Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6976011 | 0.91 | PTGS2 (0.83) | PTGS2PTGS1 | |
| SCHEMBL6975893 | 0.88 | PTGS2 (0.79) | PTGS2PTGS1 | |
| SCHEMBL5708905 | 0.87 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL1377265 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL6977214 | 0.85 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL6975889 | 0.84 | PTGS2 (0.72) | PTGS2PTGS1 | |
| SCHEMBL6975614 | 0.83 | PTGS2 (0.83) | PTGS2PTGS1 | |
| SCHEMBL6968964 | 0.82 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL6972681 | 0.81 | PTGS2 (0.77) | PTGS2PTGS1 | |
| SCHEMBL6974584 | 0.81 | PTGS2 (0.78) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4717211-B2 | — | — | 2011-07-06 | — | — | JP | claimed |
| US-6518303-B2 | Selectively inhibit COX-2 in preference to COX-1 and are useful in the treatment of COX-2 mediated diseases, such as inflammation, pain, fever and asthma with fewer side effects | ALMIRALL PRODESFARMA S.A. (ES) | 2003-02-11 | — | — | US | claimed |
| EP-1115716-B1 | 2-PHENYLPYRAN-4-ONE DERIVATIVES | ALMIRALL PRODESFARMA AG (CH) | 2003-01-02 | — | — | EP | claimed |
| JP-2002525364-A | — | — | 2002-08-13 | — | — | JP | claimed |
| US-20020045644-A1 | 2-phenylpyran-4-one derivatives | LABORATORIES ALMIRALL, S.A. (ES) | 2002-04-18 | — | — | US | claimed |
| EP-1115716-A1 | 2-PHENYLPYRAN-4-ONE DERIVATIVES | Almirall Prodesfarma, S.A. (ES) | 2001-07-18 | — | — | EP | claimed |
| WO-2000018753-A1 | 2-PHENYLPYRAN-4-ONE DERIVATIVES | ALMIRALL PRODESFARMA, S.A. (ES) | 2000-04-06 | — | — | WO | claimed |
| EP-3509604-B1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TUFTS COLLEGE (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12478609-B2 | Combination therapies using immuno-DASH inhibitors and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2025-11-25 | — | — | US | disclosed |
| US-20240277659-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2024-08-22 | — | — | US | disclosed |
| US-11957657-B2 | Combination therapies using immuno-dash inhibitors and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230390241-A1 | DASH INHIBITORS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2023-12-07 | — | — | US | disclosed |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2023-11-23 | — | — | US | disclosed |
| US-20040147581-A1 | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy | PHARMACIA CORPORATION (US) | 2004-07-29 | — | — | US | disclosed |
| WO-2004045509-A2 | METHOD OF USING A COX-2 INHIBITOR AND A 5-HT1A RECEPTOR MODULATOR AS A COMBINATION THERAPY | PHARMACIA CORPORATION (US) | 2004-06-03 | — | — | WO | disclosed |
| US-6518303-B2 | Selectively inhibit COX-2 in preference to COX-1 and are useful in the treatment of COX-2 mediated diseases, such as inflammation, pain, fever and asthma with fewer side effects | ALMIRALL PRODESFARMA S.A. (ES) | 2003-02-11 | — | — | US | disclosed |
| EP-1115716-B1 | 2-PHENYLPYRAN-4-ONE DERIVATIVES | ALMIRALL PRODESFARMA AG (CH) | 2003-01-02 | — | — | EP | disclosed |
| US-20020045644-A1 | 2-phenylpyran-4-one derivatives | LABORATORIES ALMIRALL, S.A. (ES) | 2002-04-18 | — | — | US | disclosed |
| EP-1115716-A1 | 2-PHENYLPYRAN-4-ONE DERIVATIVES | Almirall Prodesfarma, S.A. (ES) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000018753-A1 | 2-PHENYLPYRAN-4-ONE DERIVATIVES | ALMIRALL PRODESFARMA, S.A. (ES) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277659-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | HPGDS, PTGIS, PTGDR2 | PTGS2 19/4885PTGS1 16/4885 |
| US-12478609-B2 | Combination therapies using immuno-DASH inhibitors and PGE2 antagonists | HPGDS, PTGIS, PTGDR2 | PTGS2 19/4885PTGS1 16/4885 |
| US-20230390241-A1 | DASH INHIBITORS, AND USES RELATED THERETO | CD2BP2, PCNA, CD2 | PTGS2 2358/4885PTGS1 1824/4885 |
| US-20040147581-A1 | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy | HTR2A, HTR1A, TPH2 | PTGS2 19/4885PTGS1 27/4885 |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | PTGS2 24/4885PTGS1 11/4885 |
| US-11957657-B2 | Combination therapies using immuno-dash inhibitors and PGE2 antagonists | HPGDS, PTGIS, PTGDR2 | PTGS2 19/4885PTGS1 16/4885 |
| US-20020045644-A1 | 2-phenylpyran-4-one derivatives | NR4A1, CYP3A4, HTR4 | PTGS2 912/4885PTGS1 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.